

DEPARTMENT OF DEFENSE

Department of the Army

Intent to Grant an Exclusive License for U.S. Government-Owned Invention

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.

ADDRESSES: Commander, U.S. Army Medical Research and Development Command,
ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite
227, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Dr. Paul Michaels, Office of Research &
Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory
Patent Attorney, (301) 619-7808.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR
404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use,
royalty-bearing, revocable license to United States Patent 10,434,167 issued on October 8, 2019,
entitled “Non-Toxic Adjuvant Formulation Comprising a Monophosphoryl Lipid A (MPLA)-
Containing Liposome Composition and a Saponin” to Pfizer having its principal place of
business at 235 E 42nd Street, New York, New York 10017.

Anyone wishing to object to grant of this license can file written objections along with
supporting evidence, if any, within 15 days from the date of this publication. Written objections

are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).